Scarica l'app Stockscreener
9.01
0.99%
-0.09
Dopo l'orario di chiusura:
9.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CVRX Giù?
Forum
Previsione
Precedente Chiudi:
$9.10
Aprire:
$8.92
Volume 24 ore:
135.35K
Relative Volume:
0.40
Capitalizzazione di mercato:
$237.07M
Reddito:
$56.65M
Utile/perdita netta:
$-53.31M
Rapporto P/E:
-4.4076
EPS:
-2.0442
Flusso di cassa netto:
$-40.75M
1 W Prestazione:
-2.91%
1M Prestazione:
+9.61%
6M Prestazione:
+14.34%
1 anno Prestazione:
-30.59%
Intervallo 1D:
$8.66
$9.105
Intervallo di 1 settimana:
$8.47
$9.755
Portata 52W:
$4.2993
$12.70
Cvrx Inc Stock (CVRX) Company Profile
Nome
Cvrx Inc
Settore
Industria
Telefono
(763) 416-2850
Indirizzo
9201 WEST BROADWAY AVENUE, MINNEAPOLIS
Compare CVRX vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CVRX
Cvrx Inc
|
9.01 | 239.44M | 56.65M | -53.31M | -40.75M | -2.0442 |
ABT
Abbott Laboratories
|
102.87 | 177.90B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
331.54 | 126.16B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.63 | 110.49B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
62.82 | 92.14B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.05 | 46.85B | 6.07B | 1.06B | 1.34B | 1.8063 |
Cvrx Inc Stock (CVRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-09 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-01-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-09-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-11 | Reiterato | Lake Street | Buy |
| 2024-05-01 | Ripresa | Craig Hallum | Buy |
| 2024-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-05-01 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Iniziato | Lake Street | Buy |
| 2022-07-18 | Iniziato | Craig Hallum | Buy |
| 2021-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2021-07-26 | Iniziato | Piper Sandler | Overweight |
| 2021-07-26 | Iniziato | William Blair | Outperform |
Mostra tutto
Cvrx Inc Borsa (CVRX) Ultime notizie
CVRx, Inc. (NASDAQ:CVRX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Patterns Watch: Is CVRX a speculative investmentPortfolio Profit Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Sectors Review: Is CVRX a strong candidate for buy and holdInsider Buying & Technical Analysis for Trade Confirmation - baoquankhu1.vn
IMA,CVRX Volatility & Greeks - Finviz
How (CVRX) Movements Inform Risk Allocation Models - Stock Traders Daily
CVRx touts Barostim therapy as improving exercise capacity in heart failure beyond GDMT alone - Traders Union
SGP,CVRX Volatility & Greeks - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
2026-03-26 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Shareholders to Reach Out | NDAQ:CVRX | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Q4 2025 earnings call transcript - MSN
CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
IMA,CVRX Dividends - Finviz
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Investors to Connect - accessnewswire.com
CVRx’s BENEFIT-HF Trial: New Heart Failure Study Sets Up a Key Catalyst for Investors - tipranks.com
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
CVRx Inc Stock (ISIN: US12674F1003) Gains Momentum on Heart Failure Device Adoption Amid Medtech Sec - AD HOC NEWS
Sentiment Review: Will CVRX benefit from government policy2026 Price Swings & Precise Buy Zone Identification - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
EPS Watch: How is CVRx Inc managing supply chain issuesOptions Play & Daily Stock Momentum Reports - baoquankhu1.vn
Trading Systems Reacting to (CVRX) Volatility - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating CVRx, Inc. (CVRX) And Encourages Stockholders to Connect - ACCESS Newswire
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Continues – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - The AI Journal
FinancialContentCVRx, Inc. (CVRX) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation - FinancialContent
Levels Update: Whats the beta of CVRx Inc stock2026 Pullbacks & High Conviction Investment Ideas - baoquankhu1.vn
First Barostim procedure at Ascension Alexian Brothers backed by CVRx - Traders Union
CVRx (CVRX) CMO granted 62K options, 41K RSUs and sells 1.3K shares - Stock Titan
Exit Recap: Will CVRx Inc announce a stock splitMarket Rally & Long-Term Growth Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against CVRx, Inc. (CVRX) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
CVRx, Inc. (NASDAQ:CVRX) Sees Significant Increase in Short Interest - MarketBeat
IMA,CVRX Options - Finviz
Bronstein, Gewirtz & Grossman, LLC Encourages CVRx, Inc. (CVRX) Investors to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against CVRx, Inc. (CVRX) And Encourages Investors to Reach Out - ACCESS Newswire
CVRx enables first Barostim implant at Baptist Medical Center expanding heart failure treatment options - Traders Union
Buybacks Report: Does CVRx Inc meet Warren Buffetts criteria2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
CVRx outlines $55M-$57M revenue target for 2025 as sales force transition nears completion - MSN
CVRX SEC FilingsCvrx, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Energy Moves: Why is CVRx Inc stock going downMarket Sentiment Review & Smart Allocation Stock Reports - baoquankhu1.vn
CVRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CVRx shares rise on CMS inclusion for Barostim implant procedure - MSN
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates - MSN
Quarterly Earnings: Is CVRx Inc. stock affected by interest rate hikesTrade Risk Summary & High Return Stock Watch Alerts - Naître et grandir
CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
How Cvrx Inc. (CVRX) Affects Rotational Strategy Timing - Stock Traders Daily
Risk Check: Whats the beta of CVRx Inc stock2025 Macro Impact & Weekly High Return Stock Forecasts - baoquankhu1.vn
Barostim device transforms life after severe heart failure, CVRx asserts - Traders Union
Trend Recap: Why is CVRx Inc stock going downPortfolio Return Summary & Safe Capital Growth Trade Ideas - baoquankhu1.vn
CVRX Earnings History & Surprises | EPS & Revenue Results | CVRX INC (NASDAQ:CVRX) - ChartMill
CVRx to present late-breaking THT2026 data in clinical webinar - Traders Union
CVRx Introduces New Performance-Based Executive Stock Unit Plan - The Globe and Mail
CVRx (CVRX) lists Chief HR Officer Gregory Morrison as insider on Form 3 - Stock Titan
Cvrx Inc Azioni (CVRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cvrx Inc Azioni (CVRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hykes Kevin | PRES & CEO |
Mar 02 '26 |
Sale |
7.90 |
7,763 |
61,349 |
284,237 |
| VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,284 |
10,146 |
60,551 |
| OASHEIM JARED | CHIEF FINANCIAL OFFICER |
Mar 02 '26 |
Sale |
7.90 |
1,744 |
13,781 |
96,703 |
| John Robert Allen | Chief Revenue Officer |
Mar 02 '26 |
Sale |
7.90 |
3,964 |
31,326 |
86,036 |
| Jain Mudit K. | Director |
Feb 20 '26 |
Buy |
6.36 |
46,800 |
297,592 |
980,183 |
| Jain Mudit K. | Director |
Feb 18 '26 |
Buy |
4.64 |
600 |
2,785 |
5,650 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 26 '25 |
Sale |
10.03 |
6,337 |
63,560 |
4,040,861 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 24 '25 |
Sale |
10.06 |
2,200 |
22,132 |
4,047,198 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 21 '25 |
Sale |
10.00 |
500 |
5,000 |
4,049,398 |
| JOHNSON & JOHNSON | 10% Owner |
Nov 12 '25 |
Sale |
10.00 |
1,000 |
10,000 |
4,049,898 |
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):